Episodes
-
Michael Kelly, MD, PhD, a pediatric hematologist and oncologist at Cleveland Clinic Children's, joins the Cancer Advances podcast to discuss innovative care for vascular anomalies. In this episode, Dr. Kelly explains how they are exploring advanced treatments, including clinical trials using cancer medications to address these non-cancerous conditions, the impact of somatic mutations, and the evolving role of genetic research. Discover the latest advances and how these efforts aim to improve both the quality of life and outcomes for patients facing these rare and challenging conditions.
-
Inpatient Director of the Cellular and Immunotherapy Service, John Molina, MD, EdM, joins the Cancer Advances podcast to talk about the launching of the Cellular and Immunotherapy Service to manage the growing number of patients receiving cellular therapies like CAR-T and bispecific antibodies. Listen as Dr. Molina share insights on the protocols that help identify and mitigate toxicities early, reducing ICU stays and enhancing patient outcomes with the long-term goal of transitioning more patients to outpatient management where possible.
-
Episodes manquant?
-
Josephine K. Dermawan, MD, PhD, a soft tissue pathologist at Cleveland Clinic joins the Cancer Advances podcast to discuss the development of novel genomic risk stratification models for soft tissue and uterine leiomyosarcomas. Given the complexity and variety of sarcomas, accurately identifying subtypes is key to effective treatment. Listen as Dr. Dermawan explains the challenges of risk stratification and how genomic profiling enhances our ability to predict tumor behavior, leading to more precise treatment decisions.
-
Chair of the Department of Gastroenterology, Hepatology and Nutrition, Michelle Kang Kim, MD, PhD, joins the Cancer Advances podcast to discuss neuroendocrine tumors and carcinoid heart disease. Listen as Dr. Kim shares her expertise on this rare but increasingly prevalent type of cancer, the complexities of managing carcinoid heart disease, a condition seen in patients with metastatic neuroendocrine tumors, and the benefits of multidisciplinary care in treatment planning.
-
Breast Medical Oncologist, Erin Roesch, MD, joins the Cancer Advances podcast to discuss endocrine therapy for breast cancer in young patients. Listen as Dr. Roesch explains the key differences in treatment for premenopausal women, including the use of tamoxifen, ovarian suppression, and aromatase inhibitors.
-
Joshua Arbesman, MD, Dermatologist and Director of the Pigmented Lesion Clinic at Cleveland Clinic, joins the Cancer Advances podcast to talk about the genetic risks of melanoma. Listen as Dr. Arbesman delves into the inherited predispositions for melanoma, highlights key findings from his research on identifying high-risk patients and explains how genetic testing can help in early detection and personalized treatment.
-
Zeina Nahleh, MD, Cancer Center Director and Regional Chair of Hematology Oncology at Cleveland Clinic in Florida joins the Cancer Advances Podcast to discuss the latest breakthroughs in treating brain metastasis in breast cancer patients. Listen as Dr. Nahleh shares insights into the challenges of managing this complex condition, highlights key findings from her recent study, and emphasizes the critical role of combining local and systemic therapies. Discover what the future holds with emerging treatments and how they may improve patient outcomes in this evolving field.
-
Gregory Videtic, MD, Director of the Thoracic Radiation Oncology Program at Cleveland Clinic, joins the 200th episode of the Cancer Advances podcast to talk about neuroprotection in patients with small cell lung cancer. Listen as Dr. Videtic explains the findings of the NRG CC003 trial, which examined how hippocampal-sparing radiation could minimize memory-related side effects while maintaining cancer control.
-
The Cancer Advances podcast is joined by Ofer Reizes, PhD, the Laura J. Fogarty Endowed Chair for Uterine Cancer Research, and Roberto Vargas, MD, Gynecologic Oncologist and Program Director for the Gynecologic Oncology Fellowship to discuss their research on targeting CD55 to combat chemoresistance in ovarian cancer patients. Listen as they insights into the mechanisms behind chemoresistance, the challenges it presents in treatment, and the potential for innovative therapies to transform patient outcomes.
-
Arun D. Singh, MD, Director of Ophthalmic Oncology at Cleveland Clinic Cole Eye Institute, returns to the Cancer Advances podcast to discuss iris melanoma. Listen as Dr. Singh talks about the unique characteristics of this rare eye cancer, the latest advancements in diagnosis and treatment, including cutting-edge imaging techniques and the potential of machine learning. Tune in for this insightful discussion on this rare type of melanoma.
-
The Cancer Advances podcast is joined by third-year internal medicine resident, Heya Batah, MD, and hematologist and medical oncologist, Moaath Khader Mustafa Ali, MD, MPH to discuss the latest findings on the combination of atezolizumab with carboplatin and etoposide in treating extensive stage small cell lung cancer. Listen as they talk about the real-world data presented by Dr. Batah at ASCO, focusing on the impact of atezolizumab on overall survival and progression-free survival compared to traditional chemotherapy alone.
-
Shlomo Koyfman, MD, Director of Head and Neck and Skin Radiation at Cleveland Clinic, joins the Cancer Advances podcast to talk about the latest ASCO clinical practice guidelines for managing osteoradionecrosis, a potential complication due to radiation therapy. Listen as Dr. Koyfman discuss how the new guidelines are designed to enhance the prevention, early detection, and management of osteoradionecrosis. He shares insights into how these guidelines can be put into practice, and the impact of these new strategies on patient care and survivorship.
-
Thach-Giao Truong, MD, Director of the Melanoma Program at Cleveland Clinic, joins the Cancer Advances podcast to discuss Tumor-Infiltrating Lymphocyte (TIL) therapy. This cutting-edge, personalized cancer treatment utilizes a patient's immune cells to target and destroy tumors. Listen as Dr. Truong provides insights into the science behind TIL therapy, its advantages, and its potential to revolutionize treatment for patients with resistant melanoma and other challenging cancers.
-
Lily Wang, PhD, from the Department of Translational Hematology Oncology Research at Cleveland Clinic, joins the Cancer Advances Podcast to dive into her research on VISTA and LRIG1 interactions. Dr. Wang, an expert in immune mechanisms within cancer, discusses her lab's innovative work on these immune checkpoint proteins and their potential to overcome current treatment limitations. Discover how targeting the VISTA-LRIG1 axis could offer new strategies for tackling resistant tumors and improving patient outcomes.
-
Urologic Oncologist, Zeyad Schwen, MD, joins the Cancer Advances podcast to discuss prostate cancer and genomics. Learn about the latest advancements in genomic testing, its impact on diagnosis and treatment, and how these innovations shape personalized care in oncology. Dr. Schwen shares insights on the practical applications of genomics in prostate cancer, discusses ongoing research, and explores the potential future of cancer diagnostics.
-
Lukas Delasos, DO, Medical Oncologist at Cleveland Clinic, joins the Cancer Advances podcast to talk about the ADRIATRIC study. Dr. Delasos shares his insights on small cell lung cancer, detailing its aggressive nature, current treatment paradigms, and the promising results from the ADRIATIC study involving durvalumab as a consolidation therapy.
-
The Cancer Advances podcast is joined by Palliative Medicine physicians, Renato Samala, MD and Chirag Patel, MD to discuss the use of scrambler technology to treat neuropathic symptoms in cancer patients. Traditional medications for neuropathic symptoms caused by cancer treatments can be ineffective and often have side effects. Scrambler technology, which uses electrical signals to reprogram nerve signals, offers an innovative alternative. Listen as Dr. Samala and Dr. Patel explain the potential benefits of scrambler therapy, its application, patient selection, and prospects for better access and research on long-term outcomes.
-
Joel Cardenas Goicoechea, MD, MBA, a Gynecologic Oncologist at Cleveland Clinic Weston Hospital in Florida, joins the Cancer Advances podcast to discuss the benefits of robotic cytoreductive surgery combined with laparoscopic HIPEC for ovarian cancer. Listen as Dr. Cardenas explains how this innovative approach offers lower complication risks, reduced blood loss, and shorter hospital stays than traditional open surgery. Tune in to learn how these advancements enhance patient outcomes and quality of life in the treatment of ovarian cancer.
-
Gynecologic Oncologist, Peter Rose, MD, joins the Cancer Advances podcast to share insights on an exciting new clinical trial investigating adoptive immunotherapy for ovarian cancer. The trial investigates personalized T-cell therapies and their potential to transform treatment outcomes. Discover how this groundbreaking approach offers new hope in the battle against advanced ovarian cancer.
-
Holly Pederson, MD, an Oncologist and member of the medical breast team at Cleveland Clinic, joins the Cancer Advances podcast to discuss her research on using polygenic risk scores to predict early onset triple-negative breast cancer in Black women. While polygenic risk scores have shown promise in predicting breast cancer risk, they have mainly been tested in European women and are less accurate for other ancestries. Listen as Dr. Pederson talks about the complexities of genetic risk factors across different ancestries and how these scores can revolutionize early detection and prevention strategies.
- Montre plus
